tiprankstipranks
Trending News
More News >
Syngene International Ltd. (IN:SYNGENE)
:SYNGENE
India Market
Advertisement

Syngene International Ltd. (SYNGENE) AI Stock Analysis

Compare
4 Followers

Top Page

IN:SYNGENE

Syngene International Ltd.

(SYNGENE)

Select Model
Select Model
Select Model
Neutral 69 (OpenAI - 4o)
Rating:69Neutral
Price Target:
₹713.00
▲(8.30% Upside)
Syngene International Ltd. has a solid financial foundation with strong revenue growth and profitability metrics, which is the most significant factor in its score. Technical indicators suggest some short-term weakness, and valuation metrics indicate the stock may be overvalued. The absence of earnings call data and corporate events limits further insights.

Syngene International Ltd. (SYNGENE) vs. iShares MSCI India ETF (INDA)

Syngene International Ltd. Business Overview & Revenue Model

Company DescriptionSyngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States, and internationally. The company provides discovery chemistry services, such as medicinal and synthetic chemistry, library and peptide synthesis, biomolecules, organic electronic materials, and computational and analytical chemistry; and discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals. It also offers exploratory/discovery, in vitro and genetic, and developmental and reproductive toxicology services, as well as acute, sub-chronic, and chronic toxicity studies; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing services. In addition, the company provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical, central lab, biometrics and clinical data management, regulatory, medical monitoring, pharmacovigilance, and medical writing services. Further, it offers other drug modalities, which include peptides, oligonucleotide synthesis, antibody drug conjugate, PROTACs, and CAR T-cell therapy services. The company serves pharmaceutical, biotechnology, nutrition, animal health, consumer goods, specialty chemical, and other companies. It has partnerships and collaborations with Bristol-Myers Squibb Co.; Baxter Inc.; and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.
How the Company Makes MoneySyngene International Ltd. generates revenue primarily through its contract research and manufacturing services. The company's business model is based on offering end-to-end solutions to its clients, which include major global pharmaceutical and biotechnology companies. Key revenue streams include fees for research and development services, which involve drug discovery, safety assessment, and clinical development, as well as manufacturing services for small and large molecules. Syngene's strategic partnerships and long-term contracts with leading industry players, such as Bristol-Myers Squibb and Amgen, contribute significantly to its earnings. The company also invests in expanding its capabilities and infrastructure to meet growing demand and enhance service offerings, which further supports revenue growth.

Syngene International Ltd. Financial Statement Overview

Summary
Syngene International Ltd. shows solid financial performance with consistent revenue growth and strong profitability metrics. The balance sheet reflects low leverage and strong asset management. However, there is a need to improve net profit margins and enhance free cash flow retention.
Income Statement
85
Very Positive
Syngene International Ltd. has demonstrated consistent revenue growth with a revenue growth rate of 4.41% from 2024 to 2025. The gross profit margin is strong at 74.12%, indicating efficient cost management. However, the net profit margin has slightly decreased to 13.62%, which could be a potential area of concern. The EBIT and EBITDA margins are healthy at 16.78% and 31.46%, respectively, showcasing operational efficiency.
Balance Sheet
80
Positive
The company maintains a stable balance sheet with a healthy equity ratio of 69.55%, indicating strong asset backing. The debt-to-equity ratio is low at 0.12, suggesting low leverage and financial stability. Return on equity stands at 10.50%, reflecting solid shareholder returns. Overall, the balance sheet indicates financial health with a cautious approach to debt.
Cash Flow
78
Positive
Syngene International Ltd. has shown a positive free cash flow growth rate, although the rate has decreased due to capital expenditures. The operating cash flow to net income ratio is robust at 2.35, indicating efficient cash generation. The free cash flow to net income ratio is 0.80, suggesting effective capital management, but there is room for improvement in cash retention.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue36.42B36.42B34.89B31.93B25.07B20.89B
Gross Profit20.01B27.00B10.32B23.33B17.58B15.63B
EBITDA11.33B11.46B10.85B9.88B8.07B7.67B
Net Income4.96B4.96B5.10B4.64B3.96B4.05B
Balance Sheet
Total Assets67.96B67.96B61.52B58.31B55.64B48.83B
Cash, Cash Equivalents and Short-Term Investments14.22B14.22B10.77B14.11B12.81B10.65B
Total Debt5.78B5.78B5.55B8.15B10.22B8.93B
Total Liabilities20.69B20.69B18.94B22.13B22.66B20.62B
Stockholders Equity47.27B47.27B42.58B36.18B32.98B28.21B
Cash Flow
Free Cash Flow0.003.98B5.50B3.05B1.05B2.55B
Operating Cash Flow0.0011.68B10.42B8.38B5.81B7.01B
Investing Cash Flow0.00-7.45B-4.96B-6.88B-6.12B-6.28B
Financing Cash Flow0.00-1.42B-5.51B-3.40B-313.00M580.00M

Syngene International Ltd. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price658.35
Price Trends
50DMA
663.67
Negative
100DMA
651.42
Positive
200DMA
709.92
Negative
Market Momentum
MACD
-1.09
Negative
RSI
50.57
Neutral
STOCH
60.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SYNGENE, the sentiment is Neutral. The current price of 658.35 is above the 20-day moving average (MA) of 652.16, below the 50-day MA of 663.67, and below the 200-day MA of 709.92, indicating a neutral trend. The MACD of -1.09 indicates Negative momentum. The RSI at 50.57 is Neutral, neither overbought nor oversold. The STOCH value of 60.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:SYNGENE.

Syngene International Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
318.46B96.91156.88%0.81%-53.19%-94.01%
69
Neutral
₹262.37B51.99
0.19%7.41%2.88%
69
Neutral
327.51B42.527.63%0.89%-2.34%6.64%
68
Neutral
472.92B110.574.68%0.14%6.80%-75.66%
54
Neutral
576.25B76.4511.83%0.12%10.99%0.00%
54
Neutral
482.33B94.728.01%0.13%17.31%242.99%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:SYNGENE
Syngene International Ltd.
658.35
-249.39
-27.47%
IN:ASTERDM
Aster DM Healthcare Ltd.
616.15
198.96
47.69%
IN:BIOCON
Biocon Limited
368.35
3.24
0.89%
IN:GLAND
Gland Pharma Ltd.
2,017.30
238.07
13.38%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,110.00
486.51
29.97%
IN:LAURUSLABS
Laurus Labs Ltd.
923.00
456.72
97.95%

Syngene International Ltd. Corporate Events

Syngene Releases Q1 FY2026 Earnings Call Transcript
Jul 29, 2025

Syngene International Limited has announced the availability of the transcript for its Q1 FY2026 earnings call, which took place on July 24, 2025. The transcript is accessible on the company’s website, providing stakeholders with insights into the company’s financial performance and strategic direction for the quarter.

Syngene International Announces AGM and Key Resolutions for 2025
Jun 28, 2025

Syngene International Limited has announced its 32nd Annual General Meeting (AGM) scheduled for July 23, 2025, to be held via video conferencing. Key agenda items include the adoption of audited financial statements for the fiscal year ending March 31, 2025, the declaration of a final dividend of Rs. 1.25 per equity share, and the reappointment of Professor Catherine Rosenberg as a director. Additionally, the company plans to appoint M/s V Sreedharan & Associates as secretarial auditors and recommend Ms. Vinita Bali as a Non-Executive Director. These decisions are poised to impact the company’s governance and financial distribution strategy, reflecting its commitment to shareholder engagement and corporate compliance.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 18, 2025